BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37120337)

  • 1. Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter.
    Tai TW; Tsai YL; Shih CA; Li CC; Chang YF; Huang CF; Cheng TT; Hwang JS; Lu TH; Wu CH
    J Formos Med Assoc; 2023; 122 Suppl 1():S65-S73. PubMed ID: 37120337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study.
    Wu CH; Li CC; Hsu YH; Liang FW; Chang YF; Hwang JS
    J Clin Endocrinol Metab; 2023 Mar; 108(4):827-833. PubMed ID: 36317591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials.
    Jin YZ; Lee JH; Xu B; Cho M
    BMC Musculoskelet Disord; 2019 Aug; 20(1):399. PubMed ID: 31472671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
    Li P; Wu X; Li Y; Huang J
    Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study.
    Li CC; Hsu JC; Liang FW; Chang YF; Chiu CJ; Wu CH
    Aging (Albany NY); 2022 Mar; 14(5):2239-2251. PubMed ID: 35232893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
    Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
    Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019.
    Agarwal AR; Cohen JS; Jorgensen A; Thakkar SC; Srikumaran U; Golladay GJ
    Osteoporos Int; 2023 Feb; 34(2):379-385. PubMed ID: 36462054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.
    Saito T; Sterbenz JM; Malay S; Zhong L; MacEachern MP; Chung KC
    Osteoporos Int; 2017 Dec; 28(12):3289-3300. PubMed ID: 28770272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of osteoporosis screening and treatment following vertebral fracture.
    Barton DW; Behrend CJ; Carmouche JJ
    Spine J; 2019 Mar; 19(3):411-417. PubMed ID: 30142455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.
    Tsai YL; Wu CH; Li CC; Shih CA; Chang YF; Hwang JS; Tai TW
    Osteoporos Int; 2023 Oct; 34(10):1783-1791. PubMed ID: 37466659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractures and mortality in relation to different osteoporosis treatments.
    Yun H; Delzell E; Saag KG; Kilgore ML; Morrisey MA; Muntner P; Matthews R; Guo L; Wright N; Smith W; Colón-Emeric C; O'Connor CM; Lyles KW; Curtis JR
    Clin Exp Rheumatol; 2015; 33(3):302-9. PubMed ID: 25068266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
    JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.